文献速递头颈外科

口腔疣状癌患者不支持辅助放疗

Adjuvant radiotherapy is not supported in patients with verrucous carcinoma of the oral cavity.
PubMed 文献 · Laryngoscope · 2017-02-01

基于SEER数据库(1988-2013)的横断面人群分析,比较口腔疣状癌与鳞状细胞癌接受辅助放疗对总生存(OS)和疾病特异性生存(DSS)的影响。疣状癌单纯手术组OS有改善趋势但未达统计学显著(117.0 vs 71.4个月,P=0.119),DSS显著改善(217.2 vs 110.9个月,P=0.05)。疣状癌辅助放疗组OS和DSS均呈劣于鳞状细胞癌辅助放疗组的趋势。作者认为切缘阳性或局部复发时应考虑手术再切除而非辅助放疗。

要点

  • 疣状癌单纯手术组DSS显著优于手术+放疗组(217.2 vs 110.9个月,P=0.05)。
  • 疣状癌单纯手术组OS有改善趋势但未达统计学显著(117.0 vs 71.4个月,P=0.119)。
  • 疣状癌辅助放疗组OS和DSS呈劣于鳞状细胞癌辅助放疗组的趋势,提示两者生物学和放射敏感性不同。

核心结论

  • 疣状癌接受辅助放疗的总生存和疾病特异性生存均劣于单纯手术的疣状癌及手术+辅助放疗的鳞状细胞癌。
  • 作者认为切缘阳性或局部复发的患者应考虑手术再切除而非辅助放疗。

研究设计与样本

  • 横断面人群分析,病例来自监测、流行病学和最终结果(SEER)数据库(1988-2013年)。
  • 共纳入18,819例非转移性口腔疣状癌/鳞状细胞癌病例,其中疣状癌581例(3.1%),鳞状细胞癌18,238例(97.0%)。
  • 按T分期分层的Kaplan-Meier生存曲线比较疣状癌与鳞状细胞癌接受或不接受辅助放疗的生存。

主要发现

  • 疣状癌患者平均年龄69.6岁,女性占48.9%;鳞状细胞癌患者平均年龄65.3岁,女性占37.1%。
  • 疣状癌单纯手术组(N=539)对比手术+放疗组(N=40):OS为117.0 vs 71.4个月(P=0.119),呈改善趋势但未达统计学显著。
  • 疣状癌单纯手术组对比手术+放疗组:DSS为217.2 vs 110.9个月(P=0.05),差异有统计学意义。
  • 疣状癌辅助放疗组对比鳞状细胞癌辅助放疗组:OS为71.4 vs 93.0个月(P=0.992),呈劣于后者的趋势但未达统计学显著。
  • 疣状癌辅助放疗组对比鳞状细胞癌辅助放疗组:DSS为110.9 vs 162.3个月(P=0.275),呈劣于后者的趋势但未达统计学显著。

临床怎么用

  • 作者认为切缘阳性或局部复发的疣状癌患者应考虑手术再切除而非辅助放疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze the impact of adjuvant radiation therapy (RT) on overall survival (OS) and disease-specific survival (DSS) in patients with verrucous carcinoma (VC) as compared to squamous cell carcinoma (SCC) of the oral cavity. STUDY DESIGN: Cross-sectional population analysis. METHODS: Cases of nonmetastatic VC/SCC of the oral cavity were extracted from the Surveillance, Epidemiology, and End Results (SEER) database (1988-2013). Kaplan-Meier survivals, stratified according to T stage, were compared between VC and SCC for treatment with or without adjuvant RT. RESULTS: A total of 18,819 VC/SCC cases were identified. There were 581 (3.1%) VC (mean age 69.6 years, 48.9% female) versus 18,238 (97.0%) SCC (mean age, 65.3, 37.1% female) patients. Verrucous carcinoma patients receiving surgery alone (N = 539) demonstrated a trend toward improved OS versus VC patients receiving surgery and RT (N = 40) (117.0 vs. 71.4 months, respectively, P = 0.119). There was a statistically significant improvement in DSS in VC patients receiving surgery alone (217.2 vs. 110.9 months, P = 0.05). Verrucous carcinoma patients treated with adjuvant RT demonstrated a trend toward a worse OS (71.4 vs. 93.0 months, P = 0.992) and DSS (110.9 vs. 162.3 months, P = 0.275) compared to SCC treated with adjuvant RT, suggesting a different biology and radiosensitivity between VC and SCC. CONCLUSION: Verrucous carcinoma treated with adjuvant RT had a worse OS and DSS compared to both VC treated with surgery alone and SCC treated with surgery and adjuvant RT. Consideration should be given to surgical re-section rather than adjuvant RT in patients with positive margins or local recurrence. LEVEL OF EVIDENCE: 2C. Laryngoscope, 127:1334-1338, 2017.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Mohan S, Pai SI, Bhattacharyya N, et al. Adjuvant radiotherapy is not supported in patients with verrucous carcinoma of the oral cavity. Laryngoscope. 2017. PMID: 28150306. doi:10.1002/lary.26443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。